These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31258010)

  • 1. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
    Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
    Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
    Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A; Eskazan AE
    Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K; Asagiri T; Kamioka M; Kojima K
    Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
    El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
    PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and Clinical Implications of a Novel
    Stella S; Massimino M; Tirrò E; Vitale SR; Accurso V; Puma A; Pennisi MS; DI Gregorio S; Romano C; DI Raimondo F; Siragusa S; Manzella L
    Anticancer Res; 2019 Dec; 39(12):6965-6971. PubMed ID: 31810968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
    Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
    Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3
    Massimino M; Stella S; Tirrò E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; DI Raimondo F; Manzella L
    Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
    Gendron N; Belhouachi N; Morel V; Azgui Z; Maloum K; Nguyen-Khac F; Cayuela JM; Davi F; Merle-Béral H; Chapiro E
    Ann Biol Clin (Paris); 2014; 72(3):359-66. PubMed ID: 24876147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.